Patients' and primary carers' views on clozapine treatment for schizophrenia: A cross-sectional study in Qatar.

Srour, Ahmad; Eltorki, Yassin; Malik, Humayun; Alabdulla, Majid A; Hassan, Mohamed H M O; Ahmed Al Subaiey, Maha; Michael Haddad, Peter

Srour, Ahmad; Eltorki, Yassin; Malik, Humayun; Alabdulla, Majid A; Hassan, Mohamed H M O; Ahmed Al Subaiey, Maha; Michael Haddad, Peter.

Afiliação

Srour A; Department of Psychiatry, Hamad Medical Corporation, Qatar.
Eltorki Y; Department of Psychiatry, Hamad Medical Corporation, Qatar.
Malik H; College of Pharmacy, Qatar University, Qatar.
Alabdulla MA; Department of Psychiatry, Hamad Medical Corporation, Qatar.
Hassan MHMO; Department of Psychiatry, Hamad Medical Corporation, Qatar.
Ahmed Al Subaiey M; College of Medicine, Qatar University, Qatar.
Michael Haddad P; Department of Psychiatry, Hamad Medical Corporation, Qatar.

Saudi Pharm J ; 31(2): 214-221, 2023 Feb.

Article em En | MEDLINE | ID: mdl-36942276

Palavras-chave

Clozapine; GASS, Glasgow Antipsychotic Side-effects Scale; HMC, Hamad Medical Corporation; IRB, Institutional Review Board; MENA, Middle East and North Africa; MRC, Medical Research Center; NNH, Number Needed to Harm; Qatar; RCTs, Randomised Controlled Trials; Schizophrenia; Side effects; Subjective experience; WCC, White Cell Count

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prevalence_studies / Qualitative_research Idioma: En Revista: Saudi Pharm J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Qatar

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google